X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs FRESENIUS KABI ONCO. - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD FRESENIUS KABI ONCO. BIOCON LTD/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 92.6 22.1 418.3% View Chart
P/BV x 7.8 3.1 252.0% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 BIOCON LTD   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
FRESENIUS KABI ONCO.
Mar-13
BIOCON LTD/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,188176 675.0%   
Low Rs30579 388.5%   
Sales per share (Unadj.) Rs68.737.7 182.4%  
Earnings per share (Unadj.) Rs7.65.1 148.3%  
Cash flow per share (Unadj.) Rs14.06.7 207.8%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs86.342.5 203.0%  
Shares outstanding (eoy) m600.00158.23 379.2%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.93.4 321.7%   
Avg P/E ratio x98.925.0 395.7%  
P/CF ratio (eoy) x53.418.9 282.3%  
Price / Book Value ratio x8.63.0 289.0%  
Dividend payout %13.20-   
Avg Mkt Cap Rs m447,90020,135 2,224.5%   
No. of employees `0006.11.2 533.8%   
Total wages/salary Rs m9,311703 1,324.1%   
Avg. sales/employee Rs Th6,705.85,176.2 129.6%   
Avg. wages/employee Rs Th1,514.2610.4 248.1%   
Avg. net profit/employee Rs Th736.9699.6 105.3%   
INCOME DATA
Net Sales Rs m41,2345,963 691.5%  
Other income Rs m2,06218 11,455.6%   
Total revenues Rs m43,2965,981 723.9%   
Gross profit Rs m8,2911,430 579.7%  
Depreciation Rs m3,851258 1,493.2%   
Interest Rs m615-26 -2,365.4%   
Profit before tax Rs m5,8871,216 484.0%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,569342 458.5%   
Profit after tax Rs m4,531806 562.2%  
Gross profit margin %20.124.0 83.8%  
Effective tax rate %26.728.1 94.7%   
Net profit margin %11.013.5 81.3%  
BALANCE SHEET DATA
Current assets Rs m41,4865,102 813.2%   
Current liabilities Rs m21,4132,385 897.7%   
Net working cap to sales %48.745.6 106.9%  
Current ratio x1.92.1 90.6%  
Inventory Days Days64150 42.6%  
Debtors Days Days94113 83.1%  
Net fixed assets Rs m50,6615,148 984.1%   
Share capital Rs m3,000158 1,896.3%   
"Free" reserves Rs m48,8086,556 744.5%   
Net worth Rs m51,8086,732 769.6%   
Long term debt Rs m17,898952 1,879.6%   
Total assets Rs m99,89710,388 961.7%  
Interest coverage x10.6-45.8 -23.1%   
Debt to equity ratio x0.30.1 244.2%  
Sales to assets ratio x0.40.6 71.9%   
Return on assets %5.27.5 68.6%  
Return on equity %8.712.0 73.1%  
Return on capital %9.614.6 66.0%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m12,0585,298 227.6%   
Fx outflow Rs m7,3481,772 414.6%   
Net fx Rs m4,7103,525 133.6%   
CASH FLOW
From Operations Rs m6,6211,274 519.7%  
From Investments Rs m-6,840-1,204 568.0%  
From Financial Activity Rs m-2,397-196 1,222.3%  
Net Cashflow Rs m-2,612-126 2,068.1%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 81.0 25.4%  
Indian inst/Mut Fund % 8.4 0.3 2,800.0%  
FIIs % 10.7 9.6 111.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 9.1 218.7%  
Shareholders   109,995 42,599 258.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  DR. DATSONS LABS  GLENMARK PHARMA  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (4QFY18); Net Profit Up 19.8% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 19.8% YoY). Sales on the other hand came in at Rs 12 bn (up 25.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Sep 18, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS